Evaluation of the Impact of Multiple Sclerosis and Its Treatments on Women Fertility

CompletedOBSERVATIONAL
Enrollment

800

Participants

Timeline

Start Date

January 1, 2018

Primary Completion Date

December 8, 2024

Study Completion Date

December 8, 2024

Conditions
Multiple SclerosisNeuromyelitis Optica Spectrum DisordersFertility
Interventions
BIOLOGICAL

blood sample to analyse AMH level on the serum

Evaluation of MS/NMOSD inflammatory activity on the serum AMH level (ng/ml)

Trial Locations (27)

63000

CHU Clermont-Ferrand, Clermont-Ferrand

Unknown

CHU Amiens, Amiens

CHU Besancon, Besançon

CHU Bordeaux, Bordeaux

CHU Caen, Caen

AP-HP - Créteil, Créteil

CHU Dijon, Dijon

CHU Grenoble, Grenoble

CHU Lille, Lille

CHU Limoges, Limoges

Hospices Civils de Lyon, Lyon

AP-HM, Marseille

CHU Montpellier, Montpellier

CHU Nancy, Nancy

CHU Nantes, Nantes

CHU Nice, Nice

CHU Nîmes, Nîmes

Hôpital de la Pitié-Salpêtrière, Paris

Hôpital Fondation Rothschild, Paris

Hôpital Saint Antoine, Paris

CHI Poissy- Saint-Germain-en-Laye, Poissy

CHU Poitiers, Poitiers

CHU Rennes, Rennes

CHU Strasbourg, Strasbourg

CHU Toulouse, Toulouse

CHU Tours, Tours

CHU Fort-de-France, Fort-de-France

All Listed Sponsors
collaborator

Observatoire Français de la sclérose en plaques (OFSEP)

UNKNOWN

collaborator

Roche Diagnostic Ltd.

INDUSTRY

collaborator

ARSEP foundation

UNKNOWN

lead

University Hospital, Clermont-Ferrand

OTHER

NCT07164924 - Evaluation of the Impact of Multiple Sclerosis and Its Treatments on Women Fertility | Biotech Hunter | Biotech Hunter